Day: August 10, 2023

CALGARY, Alberta, Aug. 10, 2023 (GLOBE NEWSWIRE) — Maxim Power Corp. (“MAXIM” or the “Corporation”) (TSX: MXG) announced today the release of financial and operating results for the second quarter and six months ended June 30, 2023. The unaudited condensed consolidated interim financial statements, accompanying notes and Management’s Discussion and Analysis (“MD&A”) will be available on SEDAR+ and on MAXIM’s website on August 10, 2023. All figures reported herein are Canadian dollars unless otherwise stated. FINANCIAL HIGHLIGHTS  Three Months Ended June 30, Six Months EndedJune 30,($ in thousands except per share amounts) 2023 2022 2023 2022Revenue         – 48,380 – 84,172Net income 5,964 8,565 13,715 25,463Earnings per share – basic 0.12 0.17 0.27 0.51Earnings...

Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 (GLOBE NEWSWIRE) — Predictive Oncology (Nasdaq: POAI), a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023. Q2 2023 and Recent Highlights:Initiated PEDAL-Cancer Research Horizons collaboration for the analysis of drug compounds; Initiated strategic collaboration with Cvergenx to identify novel...

Revenue in USDRevenue in USDAdjusted EBITDA & Operating Income (Loss) in USD $Adjusted EBITDA & Operating Income (Loss) in USD $NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES HALIFAX, Nova Scotia, Aug. 10, 2023 (GLOBE NEWSWIRE) — NOVA LEAP HEALTH CORP. (TSXV: NLH) (“Nova Leap” or “the Company”), a growing home health care organization, is pleased to announce the release of financial results for the quarter ended June 30, 2023. All amounts are in United States dollars unless otherwise specified. Nova Leap Q2 2023 Financial Results Financial results for the second quarter ended June 30, 2023 include the following:Q2 2023 revenues of $6,677,360 increased by 4.4% relative to Q1 2023 revenues of $6,396,076 and were lower than Q2 2022 revenues of $6,986,758 by 4.4%.Nova...

MONTRÉAL, Aug. 10, 2023 (GLOBE NEWSWIRE) — Saputo Inc. (TSX: SAP) (we, Saputo or the Company) reported today its financial results for the first quarter of fiscal 2024, which ended on June 30, 2023. All amounts in this news release are in millions of Canadian dollars (CDN), except per share amounts, unless otherwise indicated, and are presented according to International Financial Reporting Standards (IFRS). “Our business delivered solid results in the first quarter in the face of significant commodity market headwinds and lower consumer demand. We had another quarter of adjusted EBITDA and margin growth with a strong performance in our Canada Sector, significant operational improvements in our Australia division, and more operational stability in the USA Sector. Despite unprecedented market conditions, the underlying health of...

First quarter caps best four consecutive quarters on recordAdjusted EBITDA* increased 108% to $1.3 million year-over-year Total revenues grew 47% to $10.5 million year-over-year System sales revenues increased 73% to $7.5 million year-over-year Rights for use, rental and maintenance revenues of $3.0 million – best on record Net income of $0.5 million, or $0.002 per shareMONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) — D-BOX Technologies Inc. (“D-BOX” or the “Corporation”) (TSX: DBO) a world leader in haptic and immersive experiences, today reported financial results for the first quarter ended June 30, 2023. All dollar amounts are expressed in Canadian currency. “We continue to execute our plan for delivering profitable growth,” said Sébastien Mailhot, President and Chief Executive Officer of D-BOX. “Following the strong...

TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Shawcor Ltd., dba Mattr Infratech (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and six months ended June 30, 2023. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (MD&A) and interim consolidated financial statements for the three and six months ended June 30, 2023, which are available on the Company’s website and at www.sedarplus.ca. Highlights from the second quarter include1:On a consolidated basis, revenue was $401 million, income from operations was $28 million and Adjusted EBITDA was $67 million; Composite Technologies (formerly known as Composite Systems) segment set a new quarterly revenue record, increasing by 11% to $150 million compared to $135 million in...

MARLBOROUGH, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2023 and provided a business update. “Following FDA clearance of our IND for PH-762, we are moving forward with plans for a clinical trial for stages one, two and four of cutaneous squamous cell (cSCC), stage four melanoma and Merkel cell,” said Robert Bitterman, President and CEO. The initial multi-center, dose-escalating, Phase 1b clinical trial is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally injected PH-762, assess the tumor response, and determine the dose...

– Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer – – Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 – – Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to an additional $250 million in milestone payments upon the achievement of certain return thresholds – – As of June 30, 2023, Sutro had cash and investments of $358.3 million and shares of Vaxcyte common stock valued at $33.3 million, which together provide a projected cash runway into the first half of 2025...

Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) — Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced second-quarter 2023 financial results and provided a corporate update. “We continue to make progress advancing our lead candidate AL102, which is being evaluated in the ongoing Phase 3 registration-enabling RINGSIDE for the treatment of desmoid tumors. We recently concluded an instructive and successful End-of-Phase-2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) and have...

Topline Results from Four CNS Clinical Trials Expected in the Third and Fourth Quarters of 2023 Fibromyalgia Topline Results Expected in the Fourth Quarter of 2023 for Phase 3 Potentially NDA-Enabling Study of the Centrally-Acting Non-Opioid Analgesic TNX-102 SL Completed Strategic Acquisition of Two Marketed Acute Migraine Products: Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) CHATHAM, N.J., Aug. 10, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2023, and provided an overview of recent operational highlights. “We have recently completed enrollment in four clinical trials for central nervous system (CNS) indications, representing our continuing...